| Literature DB >> 34483621 |
Samuel Abosse1, Chalachew Genet2, Awoke Derbie2,3,4.
Abstract
BACKGROUND: Surgical wound infections (SWI) remain as a major source of postoperative illness that increases the time of hospital stay and health care related costs globally. On top of this, the emergence and spread of drug-resistant pathogens continue to challenge the proper management of surgical wound infections.Entities:
Keywords: Felege Hiwot Referral Hospital; Surgical wound infection; antimicrobial resistance
Mesh:
Substances:
Year: 2021 PMID: 34483621 PMCID: PMC8365483 DOI: 10.4314/ejhs.v31i3.21
Source DB: PubMed Journal: Ethiop J Health Sci ISSN: 1029-1857
Socio-demographic and clinical characteristics of study participants presumptive for SWI at FHRH, February 2019
| Variable | Frequency | Percent |
|
| ||
|
| 98 | 59.4 |
|
| 67 | 40.6 |
|
| ||
|
| 37 | 22.4 |
|
| 87 | 52.7 |
|
| 31 | 18.8 |
|
| 10 | 6.1 |
|
| ||
|
| 42 | 25.5 |
|
| 79 | 47.9 |
|
| 23 | 13.9 |
|
| 21 | 12.7 |
|
| ||
|
| 52 | 31.5 |
|
| 59 | 35.7 |
|
| 18 | 10.9 |
|
| 25 | 15.2 |
|
| 11 | 6.7 |
|
| ||
|
| 69 | 41.8 |
|
| 96 | 58.2 |
|
| ||
|
| 67 | 40.6 |
|
| 41 | 24.8 |
|
| 26 | 15.8 |
|
| 17 | 10.3 |
|
| 14 | 8.5 |
|
| ||
|
| 30 | 18.2 |
|
| 51 | 30.9 |
|
| 43 | 26.1 |
|
| 41 | 24.8 |
|
| ||
|
| 56 | 33.9 |
|
| 68 | 41.2 |
|
| 28 | 17.0 |
|
| 13 | 7.9 |
Bacterial profile of SWI patients attending at FHRH, February 2019
| SWI cases (n=115) | Frequency | Percentage | |
|
| |||
|
| 24 | 20.9 | |
|
| |||
|
| 19 | 16.5 | |
|
| 16 | 13.9 | |
|
| 10 | 8.7 | |
|
| 12 | 10.4 | |
|
| 8 | 7 | |
|
| 7 | 6.1 | |
|
| 6 | 5.2 | |
|
| 3 | 2.6 | |
|
| |||
|
| 1 | 0.87 | |
|
| 1 | 0.87 | |
|
| 1 | 0.87 | |
|
| |||
|
| 5 | 4.35 | |
|
| 2 | 1.74 | |
|
| |||
|
|
|
| |
SWI: Surgical wound infection, Single isolate= when one bacterial species/genus identified, Mixed isolates= when two bacterial species/genus identified
Antimicrobial resistance profile of S. aureus isolated from patients with SWI at FHRH, February 2019
| Bacterial isolates | Resistant isolate: Number (%) | |||||||||
|
| ||||||||||
| Amo | Amp | Ox | Ery | Gen | Cip | Ch | Tet | Van | Cl | |
|
| 27 | 22 | 10 | 12 | 5 | 5 | 11 | 12 | 3 | 8 |
|
| (87.1) | (71.0) | (32.3) | (38.7) | (16.1) | (16.1) | (35.5) | (38.7) | (9.7) | (25.8) |
Note: Amo: amoxicillin, Amp: Ampicillin, Ox: Oxacillin, Ery: Erythromycin, Gen:Gentamycin, Cip: Ciprofloxacin, Ch: Chloramphenicol, Tet: Tetracycline, Van:Vancomycin, Cl: Clindamycin
Antimicrobial resistance profile of Gram-negative bacteria isolated from patients with SWI at FHRH, February 2019
| Bacterial | Resistant isolate: Number (%) | |||||||||
|
| ||||||||||
| Amp | 0Mem | Gen | Cip | Ch | Tet | Ag | Ctx | Cef | Cez | |
|
| 22 | 6 | 10 | 5 | 9 | 13 | 14 | 16 | 15 | 14 |
|
| 14 | 2 | 2 | 4 | 5 | 10 | 8 | 9 | 10 | 9 |
|
| 10 | 2 | 4 | 5 | 5 | 7 | 7 | 8 | 7 | 9 |
|
| 9 | 5 | 4 | 5 | 3 | 8 | 5 | 9 | 8 | 8 |
|
| 8 | 3 | 2 | 3 | 4 | 7 | 6 | 7 | 8 | 6 |
|
| 8 | 2 | 2 | 4 | 4 | 7 | 5 | 6 | 7 | 6 |
|
| 6 | 1 | 2 | 3 | 3 | 4 | 3 | 5 | 4 | 5 |
|
| 3 | 0 | 0 | 1 | 2 | 2 | 1 | 2 | 1 | 1 |
Note: Amp: Ampicillin, Mem: Meropenem, Gen: Gentamycin, Cip: Ciprofloxacin, Ch:Chloramphenicol, Tet: Tetracycline, Ag: Augmentin, Ctx: cefotaxime, Cef: Cefoxitin, Cez: Ceftazidime
Figure 1Multidrug resistance profile of bacterial isolates from patients with SWI at FHRH, Feb 2019.
Note: SA: S. aureus, PsA: P. aeruginosa, KSpp: Klebsiella Spp., EC: E. coli, CSpp: Citrobacter Spp., ASpp: Acinetobacter Spp., PSpp: Proteus Spp., ESpp: Enterobacter Spp., SSpp: Serratia Spp., MDR: Multidrug resistance
Factors associated with culture positive SWI at FHRH, February 1 to June 30, 2019
| Variables | Bacterial occurrence | COR, 95% CI | (AOR;95% CI), | |
|
| ||||
| Positive: | Negative: | |||
|
| ||||
| Clean | 11 (9.65%) | 19(37.25%) | 1 | 1 |
| Clean-contaminate | 31 (27.19%) | 20(39.23%) | 78.2, 23.5–26.8 | (2; 0.739–5.452), 0.172 |
| Contaminate | 33 (28.95%) | 10(19.61%) | 10.4, 3.1–35.3 | (5.5; 1.891–16.097), 0.002 |
| Dirty | 39 (34.21%) | 2 (3.92%) | 18.4, 2.0–176.4 | (36.4; 7.115–185.281), |
| Duration of hospital | ||||
|
| 24 (21.05%) | 30(58.82%) | 1 | 1 |
|
| 59 (51.75%) | 14(27.45%) | 4.1, 1.9–9.1 | (5.3; 2.385–11.633), 0.001 |
|
| 20 (17.54%0 | 6 (11.76%) | 3.2, 1.2–8.2 | (4.2; 1.446–12.009), 0.008 |
|
| 11 (9.65%) | 1 (1.96%) | 12.9, 1.6–105.9 | (13.8; 1.657–114.132), |
CI: confidence interval; AOR: adjusted odds ratio